Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio reports clinical, financial, and corporate updates tied to seralutinib, its investigational inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Recurring developments include Phase 3 study results, regulatory pathway updates, collaboration activity with Chiesi Group, quarterly financial results, and capital allocation updates.
Company news also covers Nasdaq Rule 5635(c)(4) employment inducement grants under the 2023 Employment Inducement Incentive Award Plan, investor conference participation, and business development or resource-allocation actions related to its pulmonary hypertension strategy.
Gossamer Bio has appointed Faheem Hasnain as Chief Executive Officer and President, succeeding Sheila Gujrathi, who served in the role since July 2018. Hasnain, a co-founder, previously led Receptos, Inc. before its acquisition by Celgene. In his new role, Hasnain aims to advance Gossamer's therapeutic pipeline in immunology, inflammation, and oncology. Dr. Gujrathi will remain as an advisor. The transition occurs as the company navigates the complexities of clinical-stage biopharmaceutical development, with a focus on unmet patient needs.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q3 2020 financial results, highlighting ongoing advancements in its clinical trials for GB002, GB004, and GB1275. GB002's Phase 2 trial for pulmonary arterial hypertension is set to enroll patients in Q4 2020, with topline data expected in H1 2022. GB004 is in a Phase 2 trial for inflammatory bowel disease, also targeting H1 2022 for topline data. Financially, Gossamer holds $555.4 million in liquid assets but reported a $57.8 million net loss for the quarter, influenced by increased interest expenses.
Gossamer Bio, Inc. (GOSS) will report its third quarter 2020 financial results on November 10, 2020. A live conference call will take place at 4:30 p.m. ET, allowing the management team to discuss the financial results and provide corporate updates. Interested parties can join the call using the domestic number (833) 646-0603 or international number (929) 517-9782. A subsequent audio webcast will be available for 30 days on their website.
Gossamer Bio (Nasdaq: GOSS) announced it will present data on GB1275 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held virtually from November 9-14, 2020. The presentation will include clinical and biomarker data from the ongoing Phase 1/2 trial, KEYNOTE-A36, focusing on advanced solid tumors. Two key posters will be presented by Dr. Johanna Bendell and Dr. Wells Messersmith, detailing the preliminary results and immune biomarker evaluations of GB1275, a CD11b modulator.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced topline results from its Phase 2b LEDA trial for GB001 in patients with moderate-to-severe eosinophilic asthma and the Phase 2 TITAN trial for chronic rhinosinusitis. While the primary endpoint in the LEDA trial was not met, the results showed consistent numeric reductions in asthma worsening across all doses. Statistically significant improvements were noted in the secondary endpoint of time to first asthma worsening. The TITAN trial did not achieve its endpoints, leading to the decision not to pursue further development in that area.
Gossamer Bio (Nasdaq: GOSS) announced updates on its GB004 program targeting inflammatory bowel disease. At the UEGW Virtual Week 2020, data were presented from a Phase 1b study of GB004 in mild-to-moderate ulcerative colitis, showing safety and promising efficacy. Key outcomes included 17% mucosal healing and significant reduction in the inflammatory biomarker fecal calprotectin (38% reduction). The company is now screening patients for a global Phase 2 study (NCT04556383) with a primary endpoint of clinical remission at week 12, involving up to 195 subjects.
Gossamer Bio, Inc. (Nasdaq: GOSS) will present data on GB004 at the upcoming United European Gastroenterology Virtual Week 2020, from October 11-13. The oral presentation by Dr. William Sandborn will discuss clinical data from the completed Phase 1b trial for patients with active mild-to-moderate ulcerative colitis. Two sessions will showcase GB004's safety and protective effects on epithelial cells, signaling its potential in treating inflammatory bowel disease.